Combined SSTR2-targeted Analogue with 177Lu-DOTATATE radionuclide and octreotide therapy for refractory meningioma: a case report - Takeaways - MDSpire

Combined SSTR2-targeted Analogue with 177Lu-DOTATATE radionuclide and octreotide therapy for refractory meningioma: a case report

  • By

  • Carlen A. Yuen

  • Mahbod Jafarvand

  • David O. Kamson

  • Eleanor Chu

  • Jennifer E. Soun

  • William H. Yong

  • Frank P. Hsu

  • Hansen Bow

  • Michelle Zheng

  • Shyam M. Srinivas

  • June 11, 2026

  • 0 min

Share

  • 1

    Meningiomas are the most common primary intracranial tumors in adults, with limited standard treatment options beyond surgery and radiation.

  • 2

    Somatostatin receptor 2 (SSTR2) is overexpressed in meningiomas, making SSTR-targeted therapies like octreotide a potential treatment strategy.

  • 3

    177Lu-DOTATATE, a β-emitting peptide receptor radionuclide therapy, shows promise in treating refractory meningiomas when combined with octreotide.

  • 4

    The first case study of a refractory meningioma patient treated with combined PRRT and octreotide demonstrated stable disease and tumor regression.

  • 5

    Combination therapy with PRRT and octreotide may provide a rational approach to overcoming resistance mechanisms in refractory meningiomas.

Original Source(s)

Combined SSTR2-targeted Analogue with 177Lu-DOTATATE radionuclide and octreotide therapy for refractory meningioma: a case report

  • by Carlen A. Yuen, Mahbod Jafarvand, David O. Kamson, Eleanor Chu, Jennifer E. Soun, William H. Yong, Frank P. Hsu, Hansen Bow, Michelle Zheng, Shyam M. Srinivas

  • June 11, 2026

Related Content

Correction: Converting an immunologically “cold” tumor: Exceptional response to cadonilimab plus chemotherapy in microsatellite-stable pancreatic cystadenocarcinoma

Why CAR T cell therapy fails in renal cell carcinoma

Construction and validation of a preoperative malignancy risk prediction model for ovarian-adnexal masses based on clinical and ultrasonographic features